CIK 0001497253
- Non-accelerated filer
- Smaller reporting company
VivoSim Labs, INC.
Sign in to watch- Ticker
- VIVS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Mar 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 271488943
- Phone
- +1 858-224-1000
- Business address
- 11555 SORRENTO VALLEY ROAD, SUITE 100, SAN DIEGO, CA, 92121
- Former names
- ORGANOVO HOLDINGS, INC., REAL ESTATE RESTORATION & RENTAL, INC.
- Open-market buys, last 90 days
- $2,804
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$2,804. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 60 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2016-08-17 | Malloy Kirk Director | Grant or award · Stock Option (Right to Buy) | +18,500 | 18,500 | ||
| 2016-08-17 | KESSEL MARK Director | Grant or award | +7,500 | 7,500 | ||
| 2016-08-17 | KESSEL MARK Director | Grant or award | +7,500 | 15,000 | ||
| 2016-08-17 | KESSEL MARK Director | Grant or award · Stock Option (Right to Buy) | +18,500 | 18,500 | ||
| 2016-08-17 | KESSEL MARK Director | Grant or award · Stock Option (Right to Buy) | +18,500 | 18,500 | ||
| 2016-08-17 | HOWSON TAMAR D Director | Grant or award | +7,500 | 7,500 | ||
| 2016-08-17 | HOWSON TAMAR D Director | Grant or award · Stock Option (Right to Buy) | +18,500 | 18,500 | ||
| 2016-08-17 | GLOVER JAMES T Director | Grant or award | +7,500 | 17,500 | ||
| 2016-08-17 | GLOVER JAMES T Director | Grant or award · Stock Option (Right to Buy) | +18,500 | 18,500 | ||
| 2016-08-17 | Baltera Robert Jr. Director | Grant or award | +7,500 | 146,006 | ||
| 2016-08-17 | Baltera Robert Jr. Director | Grant or award · Stock Option (Right to Buy) | +18,500 | 18,500 | ||
| 2016-08-05 | David Eric CSO & EVP Pre-Clinical Dev | Sale | −20,000 | $4.55 | $91K | 706,306 |
| 2016-07-11 | Presnell Sharon Collins Chief Scientific Officer | Grant or award | +50,000 | 119,064 | ||
| 2016-07-11 | Presnell Sharon Collins Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2016-07-11 | Murphy Keith Chairman, CEO and President | Grant or award | +208,000 | 6,127,638 | ||
| 2016-07-11 | Murphy Keith Chairman, CEO and President | Grant or award · Stock Option (Right to Buy) | +415,000 | 415,000 | ||
| 2016-07-11 | Gallant Paul General Manager | Grant or award | +47,500 | 47,500 | ||
| 2016-07-11 | Gallant Paul General Manager | Grant or award · Stock Option (Right to Buy) | +95,000 | 95,000 | ||
| 2016-07-11 | David Eric CSO & EVP Pre-Clinical Dev | Grant or award | +50,000 | 726,306 | ||
| 2016-07-11 | David Eric CSO & EVP Pre-Clinical Dev | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 |
Page 11 of 13 · 259 trades